Verana Health, which analyzes large registries of anonymized patient data to help drug development, raises $100M from investors including GV and Bain Capital
Context & Ripple Effects
This round extends a run GV has backed from early on: it led Verana Health's $30M Series C in 2018, when the company was still rebranding from DigiSight Technologies, and returns here alongside new money from Bain Capital. The $100M is aimed at scaling the company's core asset — large registries of anonymized patient data sold into drug development.
The raise lands mid-wave: HealthVerity pulled in its own $100M Series D for patient-data management months later, Datavant raised to connect health records while preserving privacy, and Innovaccer consolidated records, insurance, and pharmacy data. Capital is converging on the plumbing between providers' data and pharma's research budgets.
First-order effects
- Verana Health gets the balance sheet to expand its specialty registries and sign more pharmaceutical sponsors, with GV doubling down and Bain Capital buying into healthcare data for the first time in this coverage.
- Pharma R&D teams gain a better-capitalized supplier of curated, anonymized patient cohorts for clinical studies, tightening the pipeline from registry to trial design.
Second-order effects
- Rivals building adjacent layers — Datavant on privacy-safe data connection, HealthVerity on cross-industry data management — face a peer that can fund deeper registry curation, pressuring them to raise at similar scale to hold their pharma accounts.
- Bain Capital's entry foreshadows its broader healthcare-software appetite visible elsewhere in its dealmaking, including its later agreement to buy insurer-SaaS provider HealthEdge for about $2.6B.
Third-order effects
- If the funding cadence holds through Verana's later $150M Series E co-led by J&J Innovation and Novo Growth, anonymized real-world patient data hardens into a distinct, well-funded industry layer sitting between health systems and drug developers.
- As more capital chases the same registries, differentiation shifts from access to data toward curation quality and privacy architecture — the ground Datavant and HealthVerity are also staking out.
The trend: Venture and private-equity capital is consolidating around health-data platforms that convert anonymized patient records into drug-development inputs.